PyInvesting

Market research

BROOKS.NSE Brooks Laboratories Limited

NSE INR Healthcare

Latest close

Loading market data…

Test a moving-average rule with historical data.

Market cap
2B
P/E ratio
14.63
Analyst target
53
Dividend yield
Not available
Beta
1.09

Community

Investor discussion

1 comment

Admin profile picture
Admin

5 years, 5 months ago

Brooks Laboratories Limited is currently in a long term uptrend where the price is trading 18.7% above its 200 day moving average.

From a valuation standpoint, the stock is 64.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.7.

Brooks Laboratories Limited's total revenue rose by 5.2% to $209M since the same quarter in the previous year.

Its net income has increased by 9.0% to $-26M since the same quarter in the previous year.

Finally, its free cash flow fell by 56.5% to $6M since the same quarter in the previous year.

Based on the above factors, Brooks Laboratories Limited gets an overall score of 4/5.